This is the authors' abstract. We don't add key points for this paper.
Heavy metal‐induced neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and Amyotrophic lateral sclerosis (ALS) have been receiving increasing consideration due to their rising prevalence and association with environmental toxicants. Metals like lead, mercury, cadmium, and arsenic accumulate in the brain, causing oxidative stress, neuroinflammation, and neurotoxicity. However, recent advancements in nanotechnology offer promising and revolutionary strategies for detecting, mitigating, and treating these disorders. Nanoparticles (NPs), including metal‐based, polymeric, and lipid‐based nanocarriers, exhibit unique physicochemical properties that enable targeted drug delivery and detection. Additionally, biosensors incorporating nanomaterials enhance the sensitivity and analytical specificity for detecting trace metals in bio‐environmental specimens, facilitating early diagnosis and preventive interventions. This review examines the role of nanoparticles and biosensors in mitigating heavy‐metal‐induced neurotoxicity, highlighting recent advancements, challenges, and the potential for nanotechnology to revolutionize the management of neurodegenerative diseases.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nelson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: